Investing for Launch Success: Tailoring Your Strategy for Europe
New analysis of success factors for emerging, small-sized and large biopharma companies launching in Europe.
Europe is the second-largest global market after the US in drug development. Owing to this size and share, pharmaceutical companies both large and emerging usually prioritize the US followed by the top 5 European countries when launching products.
Getting the launch is crucial as it drives the overall commercial success of the product, which in turn leads to optimizing a company’s return on investments.
Despite Europe’s significance, an extensive launch analysis done by Syneos Health® estimates that approximately 90% of products launched by emerging or small-sized pharma companies and 60% of products launched by large pharma were unable to meet post-launch market expectations in European territories.
Download the article below to learn how biopharma companies can evaluate and analyze the nuanced requirements of any market to customize a holistic and robust investment approach in Europe.
Related Content
Looking for exclusive insight?
